Tesofensine Research Overview

Tesofensine is a small-molecule drug — not a peptide — that inhibits the presynaptic reuptake of dopamine, norepinephrine, and serotonin simultaneously. It is classified as a triple monoamine reuptake inhibitor (TMRI). It was originally investigated as a treatment for Parkinson's disease and Alzheimer's disease, but its most clinically visible research has been in obesity pharmacology. Despite not being a peptide, tesofensine is routinely listed by research compound vendors alongside peptides; this guide covers the compound on those terms while being transparent about its chemical class.

What Is Tesofensine?

Tesofensine (NS2330) is a phenyltropane-derived synthetic small molecule. Its molecular formula is C17H23ClN2O2 and its molecular weight is approximately 338.8 g/mol. It belongs to the same structural class as cocaine and the ADHD medication methylphenidate, but its clinical pharmacological profile and intended applications are distinct. It is not a peptide, amino acid, or peptide analog.

Tesofensine was developed by NeuroSearch (Denmark) and was in-licensed by Saniona, which has pursued it primarily under the brand name Tesomet (a fixed-dose combination with metoprolol, added to offset the tachycardic effects of the parent compound). The FDA granted Tesomet Orphan Drug Designation for hypothalamic obesity in July 2021.

Tesofensine has never received marketing approval from the FDA, EMA, or any major regulatory authority for any indication. It is not approved for the treatment of obesity, Parkinson's disease, or any other condition.

Mechanism of Action

Tesofensine blocks the dopamine transporter (DAT), norepinephrine transporter (NET), and serotonin transporter (SERT) at the presynaptic terminal, thereby increasing synaptic concentrations of all three monoamines. This combined monoaminergic enhancement produces appetite suppression, likely through hypothalamic circuits that regulate energy homeostasis, as well as enhanced energy expenditure through adrenergic and dopaminergic mechanisms.

The dopaminergic component is thought to contribute disproportionately to tesofensine’s weight loss effect compared to prior SERT-dominant agents like sibutramine. Elevated dopamine may also confer CNS stimulant properties, raising concerns about abuse potential and cardiovascular effects including increased heart rate. Metoprolol was added in the Tesomet formulation specifically to counteract the beta-adrenergic heart rate increase.

What the Research Shows

Astrup et al. (2008) published the pivotal Phase 2 TIPO-1 trial in The Lancet. This randomized, double-blind, placebo-controlled trial enrolled 203 obese adults across five Danish centers and randomized them to tesofensine 0.25 mg, 0.5 mg, or 1.0 mg, or placebo once daily for 24 weeks alongside an energy-restricted diet. Mean weight loss was 4.5%, 9.2%, and 10.6% for the three doses respectively, compared to approximately 2% for placebo. The 0.5 mg dose was judged to have the most favorable benefit-risk profile (PMID 18950853).

Adverse events with tesofensine in TIPO-1 included dry mouth, nausea, constipation, diarrhea, insomnia, and elevated heart rate (mean +7.4 bpm at 0.5 mg). These are consistent with its monoaminergic mechanism. The drug did not proceed to Phase 3 registration trials for general obesity.

Saniona’s TIPO program subsequently shifted focus to hypothalamic obesity (HO) — a rare condition caused by damage to hypothalamic appetite-regulating centers, often from craniopharyngioma surgery, cranial irradiation, or trauma. Hypothalamic obesity is notoriously refractory to standard interventions. A Phase 2 randomized controlled trial of Tesomet in adults with HO (NCT03845075) showed sustained progressive weight loss, with Tesomet well-tolerated and heart rate and blood pressure unaffected relative to placebo, supporting the Orphan Drug pathway.

It is important to note that the drug’s development trajectory for general obesity stalled. Despite the encouraging Phase 2 data, no Phase 3 registration trial has been completed, and tesofensine does not have an approved indication anywhere in the world as of 2026.

Pharmacokinetics

Tesofensine is an orally bioavailable small molecule. Peak plasma concentrations are reached within approximately 2–4 hours after oral dosing. Its elimination half-life is long — estimated at approximately 220–250 hours — resulting in substantial accumulation with once-daily dosing and a prolonged washout period. Hepatic metabolism via cytochrome P450 enzymes (primarily CYP3A4 and CYP2D6) produces active metabolites. The long half-life implies that therapeutic steady state is not reached for 1–2 weeks, and drug effects persist well beyond the last dose.

Reported Research Dose Ranges

Not medical advice. These are ranges reported in research literature, not personalized recommendations. Consult your physician.

In clinical trials, tesofensine has been evaluated at oral doses of 0.25 mg, 0.5 mg, and 1.0 mg once daily. The 0.5 mg dose was identified in TIPO-1 as offering the best balance of efficacy and tolerability for obesity. In the hypothalamic obesity program, Tesomet used 0.5 mg tesofensine combined with 50 mg metoprolol. These are controlled trial doses from supervised investigational settings, not recommendations for use outside of a formal clinical or research protocol.

Storage and Handling

Tesofensine is an oral small molecule, not a lyophilized injectable peptide. Research-grade capsules or tablets should be stored at room temperature (15–25 °C), away from moisture and direct sunlight, in a sealed container. Unlike peptides, tesofensine does not require reconstitution, refrigeration, or bacteriostatic water handling. Standard pharmaceutical oral solid storage conditions apply.

What Tesofensine Is NOT

Tesofensine is not a peptide. It is a small synthetic organic molecule. It is not a GLP-1 receptor agonist, not a fat oxidation enhancer, and not a metabolic peptide comparable to semaglutide or tirzepatide. It is not FDA-approved or EMA-approved for any indication. It is not a replacement for approved weight-loss medications. Vendor marketing that frames tesofensine alongside research peptides as a comparable compound class is inaccurate; they operate through entirely different biological mechanisms.

References

1. Astrup A et al. Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial. Lancet. 2008;372(9653):1906–1913. PMID 18950853.

2. Randomized controlled trial of Tesomet for weight loss in hypothalamic obesity. PMC9175551.

3. ClinicalTrials.gov: Tesofensine/Metoprolol in Hypothalamic Injury-induced Obesity. NCT03845075.